[
  {
    "ts": "2025-12-22T08:10:16+00:00",
    "headline": "Why The Narrative Around TAT Technologies Is Shifting Amid Margin Gains And A Tempered Outlook",
    "summary": "TAT Technologies latest price target update keeps its fair value estimate steady at about $49 per share, even as the discount rate edges up from roughly 9.39% to around 9.47% amid a slightly higher perceived risk backdrop. Analysts see resilient revenue growth of about 16.20% as validation that the company is still executing well on its long term growth story, despite more cautious assumptions around certain programs. Read on to see how this evolving narrative could impact future price target...",
    "url": "https://finance.yahoo.com/news/why-narrative-around-tat-technologies-081016792.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "6d107021-b0a3-3006-b9f6-7a749d0782a8",
      "content": {
        "id": "6d107021-b0a3-3006-b9f6-7a749d0782a8",
        "contentType": "STORY",
        "title": "Why The Narrative Around TAT Technologies Is Shifting Amid Margin Gains And A Tempered Outlook",
        "description": "",
        "summary": "TAT Technologies latest price target update keeps its fair value estimate steady at about $49 per share, even as the discount rate edges up from roughly 9.39% to around 9.47% amid a slightly higher perceived risk backdrop. Analysts see resilient revenue growth of about 16.20% as validation that the company is still executing well on its long term growth story, despite more cautious assumptions around certain programs. Read on to see how this evolving narrative could impact future price target...",
        "pubDate": "2025-12-22T08:10:16Z",
        "displayTime": "2025-12-22T08:10:16Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/4b379f9ed3f80f55476d72ed08ba4e52",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ZPrh9KfMgYJyim8JH.gr3A--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4b379f9ed3f80f55476d72ed08ba4e52.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/BfAnMgVHjexb6TNUyQdj5A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/4b379f9ed3f80f55476d72ed08ba4e52.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/why-narrative-around-tat-technologies-081016792.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-narrative-around-tat-technologies-081016792.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "TATT"
            },
            {
              "symbol": "TFC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-22T13:42:07+00:00",
    "headline": "Truist Cuts Insulet (PODD) PT but Maintains Buy as Top MedTech Pick for 2026",
    "summary": "Insulet Corporation (NASDAQ:PODD) is one of the best growth stocks to buy in 2026. On December 18, Truist lowered the firm’s price target on Insulet to $390 from $412 with a Buy rating on the shares. This sentiment was posted as part of the firm’s broader research note that previewed 2026 for MedTech. Truist expressed […]",
    "url": "https://finance.yahoo.com/news/truist-cuts-insulet-podd-pt-134207633.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "36273b78-eb86-3d87-a946-ae89df60294b",
      "content": {
        "id": "36273b78-eb86-3d87-a946-ae89df60294b",
        "contentType": "STORY",
        "title": "Truist Cuts Insulet (PODD) PT but Maintains Buy as Top MedTech Pick for 2026",
        "description": "",
        "summary": "Insulet Corporation (NASDAQ:PODD) is one of the best growth stocks to buy in 2026. On December 18, Truist lowered the firm’s price target on Insulet to $390 from $412 with a Buy rating on the shares. This sentiment was posted as part of the firm’s broader research note that previewed 2026 for MedTech. Truist expressed […]",
        "pubDate": "2025-12-22T13:42:07Z",
        "displayTime": "2025-12-22T13:42:07Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/8a7b7e24924ae3f70325cdb815aaffa7",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Truist Cuts Insulet (PODD) PT but Maintains Buy as Top MedTech Pick for 2026",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Uvn0mw8HkDYj_.pjiILouA--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/8a7b7e24924ae3f70325cdb815aaffa7.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/2EpPzWwew8rFoBkHLf8TPg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/8a7b7e24924ae3f70325cdb815aaffa7.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/truist-cuts-insulet-podd-pt-134207633.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/truist-cuts-insulet-podd-pt-134207633.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "TFC"
            },
            {
              "symbol": "PODD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]